Chemical Characterization Service
ISO 10993-18 chemistry support for teams that need clearer extractables/leachables planning, better integration of chemistry data into biological evaluation, and stronger reviewer-facing chemistry logic.
ISO 10993-18 Framing
Chemistry work aligned to the role it needs to play in the overall biological evaluation, not treated as a separate silo.
Extractables and Leachables Review
Review of what was measured, how relevant it is, and whether the chemistry actually represents the finished device.
Compound Prioritization
Help identifying what findings matter most for toxicology, waiver strategy, and reviewer questions.
Regulatory Integration
Chemistry conclusions written so they can support the BEP, BER, FDA summary, or TRA more cleanly.
Best for devices where chemistry needs to do more than sit in an appendix
Chemical characterization now sits much closer to the center of biological evaluation than it used to. For many devices, chemistry is not a supporting afterthought. It is what determines whether endpoints can be waived, whether toxicology becomes necessary, and whether the reviewer believes the biological safety argument is complete.
Polymers, Additives, or Coatings
The device includes materials or treatments that make chemistry interpretation critical to biological safety conclusions.
Fluid-Path or Blood Contact
The chemistry needs to be interpreted in a way that reflects clinically relevant exposure, not just lab output.
Lab Dataset Already Exists
You have chemistry results, but the regulatory file still needs a clear explanation of what those findings mean.
Reviewer Asked a Chemistry Question
FDA or a notified body needs better justification around extractables, leachables, or the adequacy of chemistry coverage.
What strong chemical characterization support actually covers
The work is not only about listing compounds. It is about making the chemistry useful inside the broader biological safety argument.
Device and Material Review
Assessment of which materials, coatings, processing aids, and contact states actually matter for chemistry planning.
Dataset Relevance Check
Review of whether the existing extractables or leachables dataset represents the finished device and intended clinical use meaningfully.
Compound Prioritization
Focus on the chemistry findings most likely to drive toxicology, waiver logic, or reviewer concern.
Chemistry-to-Toxicology Bridge
Clear explanation of when chemistry alone is enough and when the data needs to be carried into a full TRA.
Submission-Facing Framing
Language that can be reused in the BER, FDA narrative, or EU MDR technical file instead of leaving chemistry isolated in a lab report.
Gap Identification
Direct view of what chemistry supports the file well, what is weak, and what follow-up may still be needed.
Projects where chemistry support usually adds the most value
These are the situations where chemistry clarity often improves the file more than another round of vague biological discussion.
Devices with complex polymer systems
Where additives, stabilizers, plasticizers, pigments, or coatings are likely to become a regulatory talking point.
Extractables datasets that need interpretation
Where the raw chemistry output exists, but the submission still lacks a clear explanation of why it matters or does not matter.
Waiver-driven submission strategy
Where chemistry is one of the main reasons certain endpoints may be justified without new testing.
Implants and prolonged-contact devices
Where chemistry often needs to be tied much more carefully to exposure and toxicology concerns.
Reviewer pushback on chemistry adequacy
Where the question is not just what was measured, but whether the chemistry program is adequate for the submission claim being made.
Teams planning TRA work
Where the chemistry package needs to be reviewed and structured before a toxicological risk assessment can be scoped properly.
How a chemistry scope is usually structured
The work starts with what the device is made of and what chemistry evidence already exists, then focuses on how that chemistry should be interpreted in the regulatory file.
Review Materials and Use Context
The device, patient-contact state, materials, coatings, and manufacturing context are reviewed first.
Assess the Chemistry Dataset
Existing lab outputs or planned chemistry work are checked for regulatory relevance and device representation.
Interpret the Findings
The chemistry is translated into a regulatory narrative that identifies what is informative, what is weak, and what needs escalation.
Integrate or Escalate
The output is positioned for direct use in the BEP, BER, or TRA, depending on what the file actually needs.
Questions teams usually ask before starting chemistry support
Do you run the lab testing yourself?
No. The service focuses on chemistry strategy, interpretation, and regulatory integration. Existing or external lab datasets can be reviewed and translated into the submission logic.
Is this the same as a TRA?
No. TRA is downstream toxicological interpretation. Chemical characterization support focuses first on the chemistry program and what the chemistry findings actually mean for the file.
Can this help with test waivers?
Yes. Good chemistry can strengthen certain waiver strategies, especially when combined with the right toxicological and literature support.
Can you review a lab report we already have?
Yes. That is one of the most common use cases, particularly when the report exists but has not yet been translated into submission-facing conclusions.
Need stronger chemistry support in the biological evaluation?
Send the device type, materials, current chemistry status, and regulatory pathway. I will review the likely chemistry scope and tell you the best next step.